Portal de Periódicos da CAPES

Hypereosinophilic syndrome: Long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant

2004; Wiley; Volume: 78; Issue: 1 Linguagem: Inglês

10.1002/ajh.20214

1096-8652

Maureen Cooper, Luke P. Akard, James Thompson, Michael J. Dugan, Jan B.�M.�J. Jansen,

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

American Journal of HematologyVolume 78, Issue 1 p. 33-36 Case ReportFree Access Hypereosinophilic syndrome: Long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant Maureen A. Cooper, Maureen A. Cooper Indiana Oncology-Hematology Consultants, Indianapolis, IndianaSearch for more papers by this authorLuke P. Akard, Luke P. Akard Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorJames M. Thompson, James M. Thompson Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorMichael J. Dugan, Michael J. Dugan Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorJan Jansen, Corresponding Author Jan Jansen [email protected] Indiana Blood and Marrow Transplantation, Indianapolis, IndianaIndiana Blood and Marrow Transplantation, 1500 Albany (#911), Beech Grove, IN 46107Search for more papers by this author Maureen A. Cooper, Maureen A. Cooper Indiana Oncology-Hematology Consultants, Indianapolis, IndianaSearch for more papers by this authorLuke P. Akard, Luke P. Akard Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorJames M. Thompson, James M. Thompson Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorMichael J. Dugan, Michael J. Dugan Indiana Blood and Marrow Transplantation, Indianapolis, IndianaSearch for more papers by this authorJan Jansen, Corresponding Author Jan Jansen [email protected] Indiana Blood and Marrow Transplantation, Indianapolis, IndianaIndiana Blood and Marrow Transplantation, 1500 Albany (#911), Beech Grove, IN 46107Search for more papers by this author First published: 17 December 2004 https://doi.org/10.1002/ajh.20214Citations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract A 38-year-old male with progressive myeloproliferative variant of hypereosinophilic syndrome (HES) underwent allogeneic bone marrow transplantation from a matched unrelated donor. The preparative regimen consisted of TBI, cytarabine, and cyclophosphamide. The graft was T-cell-depleted. The patient had slow, but complete, hematologic recovery, and all cells were shown by VNTR analysis to be of donor origin. Five months after transplant, the patient developed prominent eosinophilia (peak 4.1 × 109/L) with dermatographism and very high IL-5 levels. Eosinophils isolated to purity by cell sorting were all of donor origin. Mild increase in immunosuppression led to a normalization of eosinophil count after about 6 months. The patient is now 6 years after transplant, off all medications, and without evidence of disease. Allogeneic stem-cell transplantation is a potentially curative therapy for HES. Am. J. Hematol. 78:33–36, 2005. © 2004 Wiley-Liss, Inc. REFERENCES 1Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759– 2779. 2Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7: 21– 25. 3Archimbaud E, Guyotat D, Guillaume C, et al. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988; 27: 302– 303. 4Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995; 90: 213– 215. 5Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 647– 648. 6Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996; 51: 164– 165. 7Sadoun A, Lacotte L, Delwail V, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 1997; 19: 741– 743. 8Basara N, Markova J, Schmetzer B, et al. Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Leuk Lymphoma 1998; 32: 189– 193. 9Chockalingam A, Jalil A, Shadduck RK, Lister J. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 1999; 23: 1093– 1094. 10Vazquez L, Caballero D, Del Cañizo C, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000; 25: 217– 218. 11Ito C, Tsuboi K, Yoshiba F, et al. Secondary eosinophilia in a patient with hypereosinophilic syndrome after allogeneic bone marrow transplantation from a sibling donor. Jpn J Clin Hematol 2001; 42: 496– 501. 12Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002; 29: 457– 458. 13Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119: 131– 134. 14Jansen J, Hanks S, Akard LP, et al. Immunomagnetic CD4 + CD8 depletion for patients at high risk for severe acute GVHD. Bone Marrow Transplant 1996; 17: 377– 382. 15Kalaycioglu ME, Bolwell BJ. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Bone Marrow Transplant 1994; 14: 113– 115. 16Cortes J, Ault P, Thomas D, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101: 4714– 4716. 17Gotlib J, Cools J, Malone JM III, et al. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879– 2891. Citing Literature Volume78, Issue1January 2005Pages 33-36 ReferencesRelatedInformation